Beijing Konruns Pharmaceutical Co Ltd (603590) — Tangible Net Worth Ratio
Beijing Konruns Pharmaceutical Co Ltd (603590) has a Tangible Net Worth Ratio of 67.2% as of March 2026. This metric is calculated by deducting intangible assets (CN¥1.15 Billion) from net assets (CN¥3.51 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See how liquid is Beijing Konruns Pharmaceutical Co Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Beijing Konruns Pharmaceutical Co Ltd Tangible Net Worth Ratio (2013–2025)
This chart shows how Beijing Konruns Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 67.2%, reflecting net assets of CN¥3.51 Billion with intangible assets of CN¥1.15 Billion CNY. See Beijing Konruns Pharmaceutical Co Ltd (603590) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Beijing Konruns Pharmaceutical Co Ltd (2013–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Beijing Konruns Pharmaceutical Co Ltd from 2013 to 2025, covering 13 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see 603590 market cap overview.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 67.4% | CN¥3.50 Billion | CN¥1.14 Billion | CN¥4.09 Billion | ▼ -1.2 pp |
| 2024 | 68.6% | CN¥3.43 Billion | CN¥1.08 Billion | CN¥3.92 Billion | ▼ -1.5 pp |
| 2023 | 70.1% | CN¥3.36 Billion | CN¥1.00 Billion | CN¥3.78 Billion | ▼ -0.7 pp |
| 2022 | 70.8% | CN¥3.19 Billion | CN¥931.51 Million | CN¥3.42 Billion | ▼ -0.6 pp |
| 2021 | 71.4% | CN¥3.13 Billion | CN¥896.24 Million | CN¥3.37 Billion | ▼ -2.1 pp |
| 2020 | 73.5% | CN¥3.08 Billion | CN¥818.21 Million | CN¥3.79 Billion | ▼ -24.3 pp |
| 2019 | 97.8% | CN¥2.73 Billion | CN¥60.30 Million | CN¥3.17 Billion | ▲ +1.0 pp |
| 2018 | 96.8% | CN¥2.48 Billion | CN¥80.44 Million | CN¥2.92 Billion | ▲ +3.4 pp |
| 2017 | 93.4% | CN¥1.36 Billion | CN¥89.62 Million | CN¥1.67 Billion | ▲ +4.7 pp |
| 2016 | 88.7% | CN¥874.92 Million | CN¥98.66 Million | CN¥1.02 Billion | ▲ +4.6 pp |
| 2015 | 84.2% | CN¥683.27 Million | CN¥108.17 Million | CN¥845.80 Million | ▲ +8.3 pp |
| 2014 | 75.9% | CN¥488.02 Million | CN¥117.69 Million | CN¥665.04 Million | ▲ +14.2 pp |
| 2013 | 61.7% | CN¥313.45 Million | CN¥120.00 Million | CN¥515.13 Million | — |